Compare COSM & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COSM | CTXR |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 18.9M |
| IPO Year | 2009 | 2010 |
| Metric | COSM | CTXR |
|---|---|---|
| Price | $0.30 | $0.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 982.5K | 957.3K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.15 | 43.38 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $65,271,815.00 | N/A |
| Revenue This Year | $54.08 | N/A |
| Revenue Next Year | $32.66 | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.93 | N/A |
| 52 Week Low | $0.28 | $0.57 |
| 52 Week High | $1.32 | $2.38 |
| Indicator | COSM | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 49.12 |
| Support Level | $0.29 | $0.66 |
| Resistance Level | $0.41 | $0.97 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 7.85 | 77.74 |
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.